 | • レポートコード：D005-00927 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、固形腫瘍治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。固形腫瘍治療の種類別市場規模（化学治療、ホルモン治療、免疫治療、標的治療）、用途別市場規模（乳がん、肺がん、大腸がん、前立腺がん、子宮頸がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Hoffmann-La Roche、Eli Lilly、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Novartis、Abbott Laboratories、Boehringer Ingelheim、Biogen Idec、Kyowa Hakko Kirin、Baxter International ・地域別グローバル市場分析 2015年-2020年 ・固形腫瘍治療の北米市場（アメリカ、カナダ、メキシコ） ・固形腫瘍治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・固形腫瘍治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・固形腫瘍治療の南米市場（ブラジル、アルゼンチン） ・固形腫瘍治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学治療、ホルモン治療、免疫治療、標的治療 ・用途別分析：乳がん、肺がん、大腸がん、前立腺がん、子宮頸がん、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Solid Tumor Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 8.1% in the forecast period of 2020 to 2025 and will expected to reach USD 156810 million by 2025, from USD 114670 million in 2019.
The Solid Tumor Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Solid Tumor Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Solid Tumor Therapeutics market has been segmented into:
Chemotherapy
Hormone Therapy
Immunotherapy
Targeted Therapy
By Application, Solid Tumor Therapeutics has been segmented into:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Solid Tumor Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Solid Tumor Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Solid Tumor Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Solid Tumor Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Solid Tumor Therapeutics Market Share Analysis
Solid Tumor Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Solid Tumor Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Solid Tumor Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Solid Tumor Therapeutics are:
Hoffmann-La Roche
Eli Lilly
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Novartis
Abbott Laboratories
Boehringer Ingelheim
Biogen Idec
Kyowa Hakko Kirin
Baxter International
Table of Contents
1 Solid Tumor Therapeutics Market Overview
1.1 Product Overview and Scope of Solid Tumor Therapeutics
1.2 Classification of Solid Tumor Therapeutics by Type
1.2.1 Global Solid Tumor Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Solid Tumor Therapeutics Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Hormone Therapy
1.2.5 Immunotherapy
1.2.6 Targeted Therapy
1.3 Global Solid Tumor Therapeutics Market by Application
1.3.1 Overview: Global Solid Tumor Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Colorectal Cancer
1.3.5 Prostate Cancer
1.3.6 Cervical Cancer
1.3.7 Others
1.4 Global Solid Tumor Therapeutics Market by Regions
1.4.1 Global Solid Tumor Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Solid Tumor Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Solid Tumor Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Solid Tumor Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Solid Tumor Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Solid Tumor Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Solid Tumor Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Hoffmann-La Roche
2.1.1 Hoffmann-La Roche Details
2.1.2 Hoffmann-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Hoffmann-La Roche SWOT Analysis
2.1.4 Hoffmann-La Roche Product and Services
2.1.5 Hoffmann-La Roche Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eli Lilly SWOT Analysis
2.2.4 Eli Lilly Product and Services
2.2.5 Eli Lilly Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AstraZeneca SWOT Analysis
2.3.4 AstraZeneca Product and Services
2.3.5 AstraZeneca Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Johnson & Johnson SWOT Analysis
2.4.4 Johnson & Johnson Product and Services
2.4.5 Johnson & Johnson Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 GlaxoSmithKline SWOT Analysis
2.5.4 GlaxoSmithKline Product and Services
2.5.5 GlaxoSmithKline Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis SWOT Analysis
2.6.4 Novartis Product and Services
2.6.5 Novartis Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Abbott Laboratories
2.7.1 Abbott Laboratories Details
2.7.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Abbott Laboratories SWOT Analysis
2.7.4 Abbott Laboratories Product and Services
2.7.5 Abbott Laboratories Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Boehringer Ingelheim SWOT Analysis
2.8.4 Boehringer Ingelheim Product and Services
2.8.5 Boehringer Ingelheim Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Biogen Idec
2.9.1 Biogen Idec Details
2.9.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Biogen Idec SWOT Analysis
2.9.4 Biogen Idec Product and Services
2.9.5 Biogen Idec Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Kyowa Hakko Kirin
2.10.1 Kyowa Hakko Kirin Details
2.10.2 Kyowa Hakko Kirin Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Kyowa Hakko Kirin SWOT Analysis
2.10.4 Kyowa Hakko Kirin Product and Services
2.10.5 Kyowa Hakko Kirin Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.11 Baxter International
2.11.1 Baxter International Details
2.11.2 Baxter International Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Baxter International SWOT Analysis
2.11.4 Baxter International Product and Services
2.11.5 Baxter International Solid Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Solid Tumor Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Solid Tumor Therapeutics Players Market Share
3.2.2 Top 10 Solid Tumor Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Solid Tumor Therapeutics Revenue and Market Share by Regions
4.2 North America Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Solid Tumor Therapeutics Revenue by Countries
5.1 North America Solid Tumor Therapeutics Revenue by Countries (2015-2020)
5.2 USA Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Solid Tumor Therapeutics Revenue by Countries
6.1 Europe Solid Tumor Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Solid Tumor Therapeutics Revenue by Countries
7.1 Asia-Pacific Solid Tumor Therapeutics Revenue by Countries (2015-2020)
7.2 China Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Solid Tumor Therapeutics Revenue by Countries
8.1 South America Solid Tumor Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Solid Tumor Therapeutics by Countries
9.1 Middle East & Africa Solid Tumor Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Solid Tumor Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Solid Tumor Therapeutics Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Hormone Therapy Revenue Growth Rate (2015-2025)
10.5 Immunotherapy Revenue Growth Rate (2015-2025)
10.6 Targeted Therapy Revenue Growth Rate (2015-2025)
11 Global Solid Tumor Therapeutics Market Segment by Application
11.1 Global Solid Tumor Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Solid Tumor Therapeutics Market Forecast by Application (2019-2024)
11.3 Breast Cancer Revenue Growth (2015-2020)
11.4 Lung Cancer Revenue Growth (2015-2020)
11.5 Colorectal Cancer Revenue Growth (2015-2020)
11.6 Prostate Cancer Revenue Growth (2015-2020)
11.7 Cervical Cancer Revenue Growth (2015-2020)
11.8 Others Revenue Growth (2015-2020)
12 Global Solid Tumor Therapeutics Market Size Forecast (2021-2025)
12.1 Global Solid Tumor Therapeutics Market Size Forecast (2021-2025)
12.2 Global Solid Tumor Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Solid Tumor Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Solid Tumor Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Solid Tumor Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Solid Tumor Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Hoffmann-La Roche Corporate Information, Location and Competitors
Table 6. Hoffmann-La Roche Solid Tumor Therapeutics Major Business
Table 7. Hoffmann-La Roche Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Hoffmann-La Roche SWOT Analysis
Table 9. Hoffmann-La Roche Solid Tumor Therapeutics Product and Solutions
Table 10. Hoffmann-La Roche Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Eli Lilly Corporate Information, Location and Competitors
Table 12. Eli Lilly Solid Tumor Therapeutics Major Business
Table 13. Eli Lilly Solid Tumor Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Eli Lilly SWOT Analysis
Table 15. Eli Lilly Solid Tumor Therapeutics Product and Solutions
Table 16. Eli Lilly Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. AstraZeneca Corporate Information, Location and Competitors
Table 18. AstraZeneca Solid Tumor Therapeutics Major Business
Table 19. AstraZeneca Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. AstraZeneca SWOT Analysis
Table 21. AstraZeneca Solid Tumor Therapeutics Product and Solutions
Table 22. AstraZeneca Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Johnson & Johnson Corporate Information, Location and Competitors
Table 24. Johnson & Johnson Solid Tumor Therapeutics Major Business
Table 25. Johnson & Johnson Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Johnson & Johnson SWOT Analysis
Table 27. Johnson & Johnson Solid Tumor Therapeutics Product and Solutions
Table 28. Johnson & Johnson Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. GlaxoSmithKline Corporate Information, Location and Competitors
Table 30. GlaxoSmithKline Solid Tumor Therapeutics Major Business
Table 31. GlaxoSmithKline Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. GlaxoSmithKline SWOT Analysis
Table 33. GlaxoSmithKline Solid Tumor Therapeutics Product and Solutions
Table 34. GlaxoSmithKline Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Novartis Corporate Information, Location and Competitors
Table 36. Novartis Solid Tumor Therapeutics Major Business
Table 37. Novartis Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Novartis SWOT Analysis
Table 39. Novartis Solid Tumor Therapeutics Product and Solutions
Table 40. Novartis Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Abbott Laboratories Corporate Information, Location and Competitors
Table 42. Abbott Laboratories Solid Tumor Therapeutics Major Business
Table 43. Abbott Laboratories Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Abbott Laboratories SWOT Analysis
Table 45. Abbott Laboratories Solid Tumor Therapeutics Product and Solutions
Table 46. Abbott Laboratories Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 48. Boehringer Ingelheim Solid Tumor Therapeutics Major Business
Table 49. Boehringer Ingelheim Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Boehringer Ingelheim SWOT Analysis
Table 51. Boehringer Ingelheim Solid Tumor Therapeutics Product and Solutions
Table 52. Boehringer Ingelheim Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Biogen Idec Corporate Information, Location and Competitors
Table 54. Biogen Idec Solid Tumor Therapeutics Major Business
Table 55. Biogen Idec Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. Biogen Idec SWOT Analysis
Table 57. Biogen Idec Solid Tumor Therapeutics Product and Solutions
Table 58. Biogen Idec Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Kyowa Hakko Kirin Corporate Information, Location and Competitors
Table 60. Kyowa Hakko Kirin Solid Tumor Therapeutics Major Business
Table 61. Kyowa Hakko Kirin Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Kyowa Hakko Kirin SWOT Analysis
Table 63. Kyowa Hakko Kirin Solid Tumor Therapeutics Product and Solutions
Table 64. Kyowa Hakko Kirin Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Baxter International Corporate Information, Location and Competitors
Table 66. Baxter International Solid Tumor Therapeutics Major Business
Table 67. Baxter International Solid Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 68. Baxter International SWOT Analysis
Table 69. Baxter International Solid Tumor Therapeutics Product and Solutions
Table 70. Baxter International Solid Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Global Solid Tumor Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 72. Global Solid Tumor Therapeutics Revenue Share by Players (2015-2020)
Table 73. Global Solid Tumor Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 74. Global Solid Tumor Therapeutics Revenue Market Share by Regions (2015-2020)
Table 75. North America Solid Tumor Therapeutics Revenue by Countries (2015-2020)
Table 76. North America Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 77. Europe Solid Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 78. Asia-Pacific Solid Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 79. South America Solid Tumor Therapeutics Revenue by Countries (2015-2020)
Table 80. South America Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 81. Middle East and Africa Solid Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 82. Middle East and Africa Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 83. Global Solid Tumor Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 84. Global Solid Tumor Therapeutics Revenue Share by Type (2015-2020)
Table 85. Global Solid Tumor Therapeutics Revenue Forecast by Type (2021-2025)
Table 86. Global Solid Tumor Therapeutics Revenue by Application (2015-2020)
Table 87. Global Solid Tumor Therapeutics Revenue Share by Application (2015-2020)
Table 88. Global Solid Tumor Therapeutics Revenue Forecast by Application (2021-2025)
Table 89. Global Solid Tumor Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Solid Tumor Therapeutics Picture
Figure 2. Global Solid Tumor Therapeutics Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Hormone Therapy Picture
Figure 5. Immunotherapy Picture
Figure 6. Targeted Therapy Picture
Figure 7. Solid Tumor Therapeutics Revenue Market Share by Application in 2019
Figure 8. Breast Cancer Picture
Figure 9. Lung Cancer Picture
Figure 10. Colorectal Cancer Picture
Figure 11. Prostate Cancer Picture
Figure 12. Cervical Cancer Picture
Figure 13. Others Picture
Figure 14. Global Solid Tumor Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Solid Tumor Therapeutics Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Solid Tumor Therapeutics Revenue Market Share in 2019
Figure 23. Global Top 10 Players Solid Tumor Therapeutics Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Solid Tumor Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 27. Global Solid Tumor Therapeutics Revenue Market Share by Regions in 2018
Figure 28. North America Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. Europe Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. South America Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. North America Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 34. North America Solid Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 35. USA Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. Canada Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Europe Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Solid Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 40. Germany Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. UK Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. France Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Russia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Italy Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Solid Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 47. China Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. Japan Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Korea Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. India Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. South America Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. South America Solid Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Brazil Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Solid Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Solid Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. UAE Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Solid Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 62. Global Solid Tumor Therapeutics Revenue Share by Type (2015-2020)
Figure 63. Global Solid Tumor Therapeutics Revenue Share by Type in 2019
Figure 64. Global Solid Tumor Therapeutics Market Share Forecast by Type (2021-2025)
Figure 65. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 66. Global Hormone Therapy Revenue Growth Rate (2015-2020)
Figure 67. Global Immunotherapy Revenue Growth Rate (2015-2020)
Figure 68. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Solid Tumor Therapeutics Revenue Share by Application (2015-2020)
Figure 70. Global Solid Tumor Therapeutics Revenue Share by Application in 2019
Figure 71. Global Solid Tumor Therapeutics Market Share Forecast by Application (2021-2025)
Figure 72. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 73. Global Lung Cancer Revenue Growth Rate (2015-2020)
Figure 74. Global Colorectal Cancer Revenue Growth Rate (2015-2020)
Figure 75. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 76. Global Cervical Cancer Revenue Growth Rate (2015-2020)
Figure 77. Global Others Revenue Growth Rate (2015-2020)
Figure 78. Global Solid Tumor Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Solid Tumor Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Solid Tumor Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 82. Europe Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 84. South America Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Solid Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
脳腫瘍治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Brain Tumor Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 10.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1552.3 million by 2025, from USD 1060.2 million in 2019. The Brain Tumo…- 腫瘍治療フィールド（TTFields）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Tumor Treating Fields (TTFields) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor Treati…
- 移行上皮がん治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Transitional Cell Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Transit…
- 黒色腫治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Melanoma Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Melanoma Therapeutics m…
- 性腺性腺間質腫瘍治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Sex Cord Gonadal Stromal Tumor Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Sex …